Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy

Journal of Magnetic Resonance Imaging

Volumn 39, Issue 2, 2014, Pages 286-292

  Kim, Kyung Ah ^a   Park, Mi Suk ^b   Ji, Hyun Jun ^c   Park, Jun Yong ^b   Han, Kwang Hyub ^b   Kim, Myeong Jin ^b   Kim, Ki Whang ^b  

^a The Catholic University of Korea   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Siemens Healthcare   (South Korea)

Author keywords

apparent diffusion coefficient; concurrent chemoradiotherapy; DCE MRI; diffusion weighted image; hepatocellular carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; GADODIAMIDE; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EXTRAVASCULAR EXTRACELLULAR VOLUME FRACTION; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGING SOFTWARE; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PERFUSION WEIGHTED IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; REFLEX CONSTANT; TREATMENT OUTCOME; VOLUME TRANSFER CONSTANT;

APPARENT DIFFUSION COEFFICIENT; CONCURRENT CHEMORADIOTHERAPY; DCE MRI; DIFFUSION-WEIGHTED IMAGE; HEPATOCELLULAR CARCINOMA;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMORADIOTHERAPY; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84892808041     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24161     Document Type: Article

References (37)

1. Kim BK, Kang WJ, Kim JK, et al. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011; 117: 4779-4787.
2. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9: 208.
3. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY,. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
4. Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009; 20: 1589-1595.
5. Yopp AC, Schwartz LH, Kemeny N, et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011; 18: 2192-9199.
6. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23: 8739-8747.
7. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18: 2210-2218.
8. Park M-S, Klotz E, Kim M-J, et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 2009; 250: 110-117.
9. DeVries AF, Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 958-965.
10. Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007; 25: 1-13.
11. Jensen LR, Garzon B, Heldahl MG, Bathen TF, Lundgren S, Gribbestad IS,. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging 2011; 34: 1099-1109.
12. Semple SI, Harry VN, Parkin DE, Gilbert FJ,. A combined pharmacokinetic and radiologic assessment of dynamic contrast-enhanced magnetic resonance imaging predicts response to chemoradiation in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2009; 75: 611-617.
13. Zahra MA, Tan LT, Priest AN, et al. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 2009; 74: 766-773.
14. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008; 7: 496-501.
15. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92: 2029-2036.
16. Cui Y, Zhang XP, Sun YS, Tang L, Shen L,. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900.
17. Reichardt W, Juettner E, Uhl M, Elverfeldt DV, Kontny U,. Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. Invest Radiol 2009; 44: 298-303.
18. Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009; 193: W301-W307.
19. Lewin M, Fartoux L, Vignaud A, Arrive L, Menu Y, Rosmorduc O,. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol 2011; 21: 281-290.
20. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 26: 4572-4578.
21. Hsu CY, Shen YC, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011; 55: 858-865.
22. Wang J, Chen LT, Tsang YM, Liu TW, Shih TT,. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 2004; 183: 713-719.
23. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B,. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009; 193: 1044-1052.
24. Chefd'hotel C, Hermosillo G, Faugeras O,. Flows of diffeomorphisms for multimodal image registration. In: Proceedings of the 1st International Symposuim on Biomedical Imaging, 2002. p 753-756.
25. Niwa T, Ueno M, Ohkawa S, et al. Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol 2009; 82: 28-34.
26. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999; 9: 53-60.
27. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004; 19: 546-554.
28. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006; 241: 839-846.
29. Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B,. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol 2013; 82: 577-582.
30. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007; 188: 1001-1008.
31. Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H,. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999; 72: 1093-1098.
32. Chandarana H, Taouli B,. Diffusion and perfusion imaging of the liver. Eur J Radiol 2010; 76: 348-358.
33. Abdullah SS, Pialat JB, Wiart M, et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 2008; 28: 390-395.
34. Kim S, Mannelli L, Hajdu CH, et al. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010; 31: 348-355.
35. Devries AF, Griebel J, Kremser C, et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001; 61: 2513-2516.
36. Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237: 492-499.
37. Taouli B, Koh DM,. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254: 47-66.